The VISION trial of tepotinib, a selective MET inhibitor, enrolled patients with non–small cell lung cancer and prospectively detected MET exon 14 (METex14) skipping in liquid biopsies (LBx) and/or tissue biopsies (TBx). The gene discussed is MET; the disease is lung cancer.